Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | DRD4 | P21917 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886574 | 0.88 | MEN1 (0.86) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL3888917 | 0.85 | KDM4E (0.64) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL3886658 | 0.84 | MEN1 (0.70) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL3896962 | 0.83 | KMT2A (0.78) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL11711163 | 0.82 | HTR1A (0.58) | KDM4EDRD4DRD2DRD3HTR6 | |
| SCHEMBL3899862 | 0.79 | RAB9A (0.58) | MEN1KMT2AKDM4EHTR6HTR2A | |
| SCHEMBL7388676 | 0.78 | MEN1 (0.58) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL11701339 | 0.76 | DRD4 (0.77) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL25471321 | 0.73 | HTR1B (0.62) | MEN1KMT2AKDM4EDRD4DRD2 | |
| SCHEMBL5735754 | 0.73 | KDM4E (0.56) | MEN1KMT2AKDM4EDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | MORLEY ANDREW DAVID | 2009-08-27 | — | — | US | disclosed |
| US-7553868-B2 | Thiophene carboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1583756-B9 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1583756-B1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215829-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | RELA, NFKBIA, CSNK1E | MEN1 4523/4885KMT2A 270/4885KDM4E 343/4885 |
| US-20060111431-A1 | Thiophene carboxanmides as inhibitors of the enzyme ikk-2 | RELA, NFKBIA, CHUK | MEN1 4269/4885KMT2A 544/4885KDM4E 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.